According to The Insight Partners, the Drug Eluting Balloon Market size is expected to reach US$ 1,377.8 Million by 2034 from US$ 714.69 Million in 2025. The market is estimated to record a CAGR of 8.55% from 2026 to 2034. The report covers the market across product, technology, end-user, and regional segments. Product segmentation includes coronary drug-eluting balloons, peripheral drug-eluting balloons, and other products, while technology segmentation includes FreePac, TransPac, EnduraCoat, and other technologies. End users include hospitals, ambulatory surgical centers, and other healthcare facilities.
Drug Eluting Balloon Market: Size, Share, Trends, Analysis, and Forecast by 2034
- 2025 Market Size: US$ 714.69 Million
- 2034 Market Size: US$ 1,377.8 Million
- CAGR (2026–2034): 8.55%
- Forecast Period: 2026–2034
- Historical Period: 2021–2024
Download Sample PDF – https://www.theinsightpartners.com/sample/TIPRE00040831
- Addressable Market: Approximately US$ 9,913.08 Million during 2026–2034
- Leading Region: North America
- Fastest-Growing Region: Asia Pacific
- Key Growth Factors: Increasing prevalence of cardiovascular diseases, advancements in balloon technology, and growing preference for minimally invasive procedures
- Major Product Segments: Coronary drug-eluting balloon, peripheral drug-eluting balloon, and other products
- Key Technologies: FreePac, TransPac, EnduraCoat, and other technologies
- Major End Users: Hospitals, ambulatory surgical centers, and other end users
Market Drivers and Trends
The increasing prevalence of cardiovascular diseases is one of the major factors driving demand for drug-eluting balloons. Coronary artery disease and peripheral artery disease continue to create a substantial need for vascular interventions. DEBs enable localized drug delivery during angioplasty and are designed to help prevent restenosis, potentially reducing the requirement for repeat procedures.
Technological advancements are another important growth factor. Manufacturers are focusing on improved balloon designs, drug formulations, coating technologies, and drug-delivery mechanisms to improve therapeutic performance. These innovations are expanding the potential applications of DEBs across vascular interventions.
The growing preference for minimally invasive procedures is also supporting market expansion. Drug-eluting balloons can be used as part of catheter-based interventions, offering advantages associated with less invasive treatment approaches, including potentially shorter recovery periods and reduced procedural complications.
Hybrid treatment approaches are emerging as an important trend. Combining drug-eluting balloons with stents or other therapeutic techniques can provide clinicians with additional options for treating complex vascular conditions. At the same time, applications in peripheral artery disease are expanding beyond the traditional focus on coronary interventions.
Regional Analysis
North America holds the highest revenue share of the Drug Eluting Balloon Market. The region benefits from advanced healthcare infrastructure, high adoption of interventional cardiovascular technologies, and the presence of major medical device companies. The US is a particularly important market due to cardiovascular disease prevalence, technological development, and demand for minimally invasive procedures.
Europe represents another significant market, supported by developed healthcare systems, increasing adoption of advanced vascular interventions, and ongoing technological advancements in cardiovascular devices.
Asia Pacific is expected to register strong growth during the forecast period. The region is estimated to grow at a CAGR of 8.55% from 2026 to 2034, with improving healthcare access, rising cardiovascular disease burden, and increasing adoption of advanced medical technologies supporting market expansion.
South and Central America, and the Middle East and Africa are also expected to present growth opportunities as healthcare infrastructure improves and access to advanced cardiovascular procedures expands.
Key Players
The major companies operating in the Drug Eluting Balloon Market include:
- Medtronic PLC
- Boston Scientific Corporation
- Becton, Dickson and Company
- Terumo Corporation
- Koninklijke Philips NV
- Cook Group Incorporated
- Biotronik
- B. Braun Melsungen AG
- SurModics Inc.
These companies are involved in developing and commercializing vascular intervention technologies and are focusing on product innovation, technological advancements, strategic collaborations, and market expansion.
Get Premium Market Research Report Here: https://www.theinsightpartners.com/buy/TIPRE00040831
About Us
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
